NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
The purpose of this clinical investigation is to evaluate the safety and effects of NKG2D-CAR-NK92 infusions in the treatment of relapsed/refractory solid tumors.
Relapsed/Refractory Solid Tumors
BIOLOGICAL: NKG2D-CAR-NK92 cells
Number of participants with adverse events evaluated with CTCAE, version 4.0, Safety evaluation, 3 months|Objective Response Rate, Solid tumors to NKG2D-CAR-NK92 cells infusions, up to one year
Disease Control Rate, up to one year|Progression-free Survival, up to one year|Overall Survival, up to one year|Quality of Life Score, We use the 26 items self-rating questionnaire WHOQOL-BREF to assess the Quality of Life Score, which measures physical health, psychological health, social relationships, and environment during the last two weeks., up to one year
The purpose of this clinical investigation is to evaluate the safety and effects of NKG2D-CAR-NK92 infusions in the treatment of relapsed/refractory solid tumors.